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Abstract The effects of the Rho-kinase inhibitor, Y-27632 [1]
on Ca2+-sensitization of force induced by arachidonic acid (AA),
phorbol 12,13-dibutyrate (PDBu), GTPQS, and by the stable
thromboxane analog, 9,11-dideoxy-9K,11K-methanoepoxy-
PGF2K (U-46619), were determined in K-toxin-permeabilized
smooth muscles. Y-27632 relaxed (up to 99%) Ca2+-sensitization
by GTPQS (10 WM) and U-46619 (1 WM), but not by PDBu
(20 WM), and reduced GTPQS-induced myosin light chain
(MLC20) phosphorylation from 28% to 17% (P = 0.002).
GTPQS-induced force sensitization was inhibited by Y-27632
more potently when the inhibitor was added during the plateau of
force than prior to stimulation. In K-toxin-permeabilized smooth
muscle, Y-27632 inhibited AA (50 WM)-induced Ca2+-sensitiza-
tion of force (by 66 þ 1.3%) and reduced MLC20 phosphoryla-
tion. In contrast, Y-27632 did not relax force Ca2+-sensitized by
AA in smooth muscle permeabilized with Triton X-100. We
conclude that (i) AA induces Ca2+-sensitization through dual
mechanisms, one mediated by Rho-kinase (or a related kinase),
and (ii) Rho-kinase is not required for phorbol ester-induced
Ca2+-sensitization.
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1. Introduction
The level of regulatory myosin light chain (MLC20) phos-
phorylation that is the primary determinant of smooth muscle
contraction can be modulated independently of [Ca2]i (re-
view in [2]) by up- or downregulating the activities of myosin
light chain kinase (MLCK) and smooth muscle myosin phos-
phatase (SMPP-1M). Inhibition of MLCK and activation of
SMPP-1M, at a given [Ca2]i, decrease the level of MLC20
phosphorylation and thereby desensitize the contractile appa-
ratus to Ca2 [3,4], whereas inhibition of SMPP-1M sensitizes
it [2,5^7]. Upstream initiators of Ca2-sensitization include
agonist-activated excitatory serpentine receptors coupled to
heterotrimeric G-proteins, agents (guanosine 5P-O-(3-thiotri-
phosphate) (GTPQS), AlF34 ) that directly activate G-proteins
(review in [7]), activators (bryostatin and phorbol esters) of
conventional and novel protein kinase Cs (PKCs) [8,9], and
arachidonic acid (AA) [10^12]. Inhibition of SMPP-1M,
achieved through a variety of parallel pathways, is the major
downstream Ca2-sensitization mechanism ([5,8,13^16]; re-
view in [2,7]). Inhibition of SMPP-1M may be direct, through
phosphorylation of its regulatory subunit ([17,18] ; review in
[6]), or indirect, by kinase C-mediated phosphorylation and
consequent activation of a protein phosphatase 1C (PP1-C)
phosphatase inhibitor [5,19,20].
The monomeric GTPase, RhoA, plays a major role in
Ca2-sensitization, and its inactivation by bacterial exoen-
zymes inhibits or blocks Ca2-sensitization ([21], and refs.
therein; [22^24]). Active RhoA (RhoAWGTP) activates Rho-
kinases, serine-threonine kinases that can phosphorylate the
regulatory subunit of SMPP-1M and inhibit its catalytic ac-
tivity [18], but whether Rho-kinases are the sole G-protein-
coupled e¡ectors of Ca2-sensitization and the relationship
between reversal of Rho-kinase-mediated Ca2-sensitization
of force and dephosphorylation of MLC20 have not been fully
determined. We used a recently developed [1] highly selective
inhibitor of Rho-kinase, Y-27632, to determine whether Rho-
kinase was an e¡ector of Ca2-sensitization induced by AA
and phorbol esters and whether relaxation induced by
Y-27632 was associated with dephosphorylation of MLC20.
2. Materials and methods
Force was measured on small strips of rabbit (2^3 kg) main or
branches of pulmonary artery with the endothelium removed by gen-
tle scraping (1^2 mm long, 300^400 Wm wide) or portal vein (3 mm
long, 200^300 Wm wide) at 20^22‡C as described previously [25].
After recording contractions evoked by high K and by agonists,
the strips were incubated in relaxing solution (G1) containing 1 mM
EGTA and 4.5 mM MgATP and permeabilized with Staphylococcus
aureus K-toxin [25^27]. For Triton X-100 permeabilization, 0.05%
(pulmonary artery) or 0.1% (portal vein) Triton X-100 was applied
to the pCa 6.0 solution for 20 or 10 min, respectively, in the presence
of 1 WM calmodulin (CaM) that was included in all solutions used
after Triton X-100 permeabilization. Forces were normalized to max-
imal Ca2 (pCa 4.5)-induced contraction.
For MLC20 phosphorylation measurement by two-dimensional iso-
electric focusing/SDS-PAGE electrophoresis and densitometry of the
colloidal gold-stained MLC20 [26], strips of K-toxin-permeabilized
main branches of pulmonary artery were stimulated with 5 WM
GTPQS at pCa 7 for 12 min. When force had reached a plateau,
Y-27632 was applied for 19 min, leading to relaxation to baseline,
and then frozen. GTPQS (5 WM) stimulated (without Y-27632) time-
matched strips were similarly frozen. Non-muscle myosin that is
present in tonic smooth muscles and co-migrates with doubly phos-
phorylated smooth muscle myosin [26,28,29] was not included in the
measurements. The e¡ect of Y-27632 on AA-sensitized MLC20 phos-
phorylation in portal vein smooth muscle was determined by a pro-
tocol designed to minimize limitations due to slow di¡usion of AA
[12]. After permeabilization with K-toxin, portal vein strips were pre-
incubated with AA (50 WM) in 1 mM EGTA containing relaxing
solution for 60 min and then stimulated with pCa 6.7 and AA.
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Y-27632 (30 WM) was added at the plateau of the contraction, and
strips were frozen when the Y-27632-induced relaxation reached
steady state (15 min); pCa 6.7 and AA-stimulated, time-matched con-
trols were similarly frozen. The levels of phosphorylation were deter-
mined as described above.
Statistical comparisons were made by unpaired Student’s t-test.
Di¡erences were considered to be signi¢cant when P6 0.05. Results
are given as means þ S.E.M.
K-Toxin was from List Biological Laboratories (Campbell, CA,
USA) and phorbol 12,13-dibutyrate (PDBu) from Gibco-BRL (Gai-
thersburg, MD, USA); Triton X-100 and GTPQS from Boehringer
Mannheim (Germany); A23187 from Calbiochem (San Diego, CA,
USA); 9,11-dideoxy-9K,11K-methanoepoxy-PGF2K (U-46619) from
Cayman Chemical (Ann Arbor, MI, USA); and Y-27632 was a gift
from Yoshitomi (Osaka, Japan).
3. Results
3.1. E¡ect of Y-27632 on U-46619-induced Ca2+-sensitization
In order to evaluate in our preparations the e¡ectiveness of
Y-27632 as an inhibitor of Ca2-sensitization, we ¢rst deter-
mined its e¡ects on U-46619-induced Ca2-sensitization of
rabbit pulmonary artery, a smooth muscle highly sensitive
to G-protein-coupled Ca2-sensitization by this thromboxane
analogue [30].
The force developed in response to a maximal concentra-
tion (1 WM) of U-46619 in the presence of 5 WM GTP was
26 þ 1.7% and was relaxed by Y-27632 (2 WM) to 3.1 þ 1.3%
(n = 5; Fig. 1). This result is consistent with those obtained on
pig coronary artery and guinea pig tracheal smooth muscles in
which Y-27632 relaxed contractions induced by agonists act-
ing on G-protein-coupled receptors: phenylephrine, hista-
mine, acetylcholine, serotonin, endothelin and U-46619 [1].
3.2. The pre- and post-exposure-dependent e¡ects of Y-27632
on GTPQS-induced Ca2+-sensitization of force and MLC20
phosphorylation and its lack of e¡ect on PDBu-induced
Ca2+-sensitization
Compared to its e¡ectiveness (Ki = 0.14 WM) in inhibiting
the Rho-kinase p160 ROCK, Y-27632 is a relatively weak
inhibitor of conventional protein kinase C (isolated from rat
brain); the respective Ki values di¡er by two orders of mag-
nitude (Table 1, Uehata et al. [1]). To determine whether the
conventional and novel PKCs that are activated by phorbol
esters are also insensitive to Y-27632 in situ, we compared its
e¡ects on, respectively, GTPQS- and PDBu-evoked Ca2-sen-
sitization of contraction.
Force induced in pulmonary artery by GTPQS (10 WM) at
pCa 7.0 was relaxed by Y-27632 (10 WM) from 40 þ 3.9% of
maximal force (at pCa 4.5) to 0.3 þ 0.3% (Fig. 2; n = 4,
P6 0.001), as expected [1]. This was associated with reduction
of the 10 WM GTPQS-induced increase in MLC20 phosphoryl-
ation from 28 þ 6.5% (n = 7) to 17 þ 4.8% (n = 6, P = 0.002). In
contrast, PDBu (20 WM)-induced force (27 þ 2.7%) was not
inhibited (Fig. 2) by Y-27632 (25 þ 2.6%; n = 6^7, P = 0.7),
which was also without e¡ect on Ca2-sensitization by a lower
concentration (5 WM) of PDBu: 26 þ 3.6% and 25 þ 1.4%
(n = 2^5, Ps 0.9).
While Ca2-sensitization of rabbit portal vein by 10 WM
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Fig. 1. Abolition of the thromboxane analogue U-46619-induced
Ca2-sensitization by the Rho-kinase inhibitor (Y-27632) in K-toxin-
permeabilized main branches of rabbit pulmonary artery at constant
Ca2. Five WM GTP necessary for G-protein-coupled Ca2-sensiti-
zation induced by agonists was present throughout the experiments.
Data summary shown in the insert. The sensitization is expressed as
the force developed in addition to the response at pCa 7.0. Force is
normalized to maximal pCa 4.5-induced contraction (means þ
S.E.M.).
Fig. 2. Summary of GTPQS- or PDBu-induced Ca2-sensitization in
rabbit pulmonary artery permeabilized with K-toxin: e¡ect of the
Rho- kinase inhibitor Y-27632. Contractions were induced by 10 WM
GTPQS and 20 WM PDBu. Ten WM Y-27632 selectively inhibited the
GTPQS-induced contraction (up to 99.2%, n = 4), but not the PDBu-
induced contraction.
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GTPQS was completely relaxed by 30 WM Y-27632 (from
49 þ 5.4% to 2 þ 1.3%, n = 3^4; Fig. 3), pre-incubation with
30 WM Y-27632 inhibited the Ca2-sensitization induced by
subsequently adding GTPQS by only 20%, from 49 þ 5.4%
(n = 4) to 39 þ 2.2% (n = 5, Ps 0.05; Fig. 3). This lowered
activity of the inhibitor was not due to its binding or catab-
olism, because transfer into fresh solution having an equal
concentration of Y-27632 (30 WM) did not result in greater
relaxation.
3.3. The di¡erent, permeabilization-dependent e¡ects of
Y-27632 on AA-induced Ca2+-sensitization
Y-27632 concentration-dependently inhibited AA (50 WM)-
induced Ca2-sensitization of force in K-toxin- (Fig. 4), but
not in Triton X-100-permeabilized rabbit portal vein, consis-
tent with the participation of the cell membrane in Rho-sig-
naling [21,22]. Furthermore, the relaxant potencies of Y-27632
(tested over 1^30 WM) on AA-induced and GTPQS-induced
contraction were similar, although the 30 WM Y-27632-in-
duced relaxation of GTPQS-induced contraction (by 97 þ
2.5%) was more complete than of AA-induced contraction
(by 66 þ 1.3%). MLC20 phosphorylation was reduced by Y-
27632 from 49 þ 3.7% (n = 11) to 38 þ 3.4% (n = 12, P6 0.05).
Vigorous permeabilization of smooth muscle with Triton
X-100 or saponin abolishes the Ca2-sensitizing e¡ect of
GTPQS, while retaining some Ca2-sensitization by AA and
by the protein phosphatase inhibitor, microcystin [21]. In con-
trast to its e¡ect on K-toxin-permeabilized preparations, in
Triton X-100-permeabilized smooth muscle Ca2-sensitization
of force by AA was not signi¢cantly inhibited by 30 WM
Y-27632 (57 þ 4.5% vs. 48 þ 2.3%, n = 3 each, Ps 0.05).
3.4. Di¡erent e¡ects of Y-27632 on Ca2+-induced contractions
in, respectively, K-toxin- and Triton X-100-permeabilized
rabbit pulmonary artery
Inactivation of RhoA with the ADP-ribosylating bacterial
exoenzyme, C3, can reduce the amplitude of submaximal
Ca2-induced contractions of smooth muscle permeabilized
with L-escin [21,31], possibly as the result of ‘constitutive’
submaximal activity of the RhoA pathway. Therefore, we
determined the e¡ects of Y-27632 on Ca2-induced tension
in K-toxin-permeabilized rabbit pulmonary artery and found
it to be [Ca2]-dependent: the lower the concentration of Ca2,
the more extensive the relaxation by Y-27632. In pulmonary
artery at pCa 6.0, 10 WM Y-27632 had no e¡ect on Ca2-
induced contractions: forces were 65 þ 3.3% and 57 þ 5.3%,
respectively, in the presence or absence of 10 WM Y-27632
(n = 4, Ps 0.25). However, the same concentration of
Y-27632 decreased contractions induced by pCa 6.3 from
23 þ 2% (n = 4) to 13 þ 1.9% (n = 4, P6 0.005). Y-27632
30 WM also inhibited submaximal Ca2-induced contraction
of rabbit portal vein permeabilized with K-toxin from
19 þ 2.6% (n = 5) to 1.4 þ 0.7% (n = 5, P6 0.05).
To determine whether the above e¡ects of Y-27632 were
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Fig. 3. Y-27632 inhibited GTPQS-induced Ca2-sensitization of force
more e¡ectively when it was added at the steady-state of GTPQS-
induced contraction than when it was added prior to the addition
of GTPQS. For the pre-incubation with Y-27632, 30 WM (portal
vein) or 10 WM (pulmonary artery) Y-27632 was added for 10 min
before the addition of GTPQS. Comparisons of GTPQS-induced
force values with pre- and post-additions of Y-27632 were highly
signi¢cantly di¡erent, *P6 0.05, as well as when the pre- and post-
Y-27632 values were compared with each other.
Fig. 4. A: Incomplete inhibition of AA-induced Ca2-sensitization
of force by the Rho-kinase inhibitor Y-27632. K-Toxin-permeabi-
lized rabbit portal vein strips were ¢rst exposed to submaximal
Ca2, which gave rise to a small contraction of only 4.3% of the
maximal pCa 4.5 contraction. Fifty WM AA was then added. B:
Summary of concentration-dependent relaxation of AA-induced
Ca2-sensitization of force by Y-27632 in K-toxin-permeabilized rab-
bit portal vein. Various concentrations of Y-27632 were added cu-
mulatively after the AA-induced contraction reached steady-state
and the magnitude of relaxation measured.
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non-speci¢c (on MLCK) or re£ected the ‘constitutive’ activa-
tion of RhoA, we determined the e¡ect of Y-27632 on Triton
X-100-permeabilized smooth muscles that are insensitive to
GTPQS [21]. Contractions of Triton X-100-permeabilized
strips of rabbit pulmonary artery induced with a [Ca2]
(pCa 6.0) and [CaM] necessary to produce submaximal forces
similar to those developed by K-toxin-permeabilized strips at
pCa 6.3 were not relaxed by Y-27632: 25 þ 3.3% (n = 4) vs.
24 þ 3% (n = 4, P = 0.8). Even increasing the concentration of
Y-27632 to 200 WM caused no inhibition of the Ca2-induced
contraction, consistent with the low inhibitory activity of
Y-27632 (Kis 250 WM) [1] for the Ca2-CaM-activated
MLCK.
4. Discussion
The inhibition of the Ca2-sensitizing e¡ects of the throm-
boxane analogue U-46619 and GTPQS in rabbit vascular
smooth muscle by the Rho-kinase inhibitor Y-27632 (Figs. 1
and 2) and its lack of a relaxant e¡ect on Ca2-induced con-
tractions (in Triton X-100-permeabilized preparations) are
consistent with its being a highly selective inhibitor of Rho-
kinase, as compared to MLCK [1]. The main new ¢nding of
our study is that Ca2-sensitization by AA, but not by PDBu,
may be at least partially mediated by Rho-kinase.
AA, a natural product of phospholipid hydrolysis by phos-
pholipase A2 and/or D, can, at concentrations comparable to
those released by GTPQS in vivo, Ca2-sensitize smooth
muscle [10,11]. AA can also activate the atypical kinase C,
PKC-j [32,33] and AA-induced Ca2-sensitization of smooth
muscle is inhibited by a pseudo-substrate inhibitor of PKC-j,
whereas a phospholipase A2 inhibitor, ONO-R5-082, inhibits
phenylephrine-induced Ca2-sensitization and AA release [12].
AA can also Ca2-sensitize extensively detergent-permeabi-
lized smooth muscles not responsive to GTPQS, and selectively
inhibits the myosin phosphatase activity of isolated SMPP-1M
in solution, probably by directly dissociating the catalytic
from the regulatory subunit [10]. The reversal of AA-induced
Ca2-sensitization by Y-27632 in K-toxin-permeabilized
smooth muscle (present study) is consistent with a mechanism
initiated by AA that involves P160 ROCK [1]. Because Ca2-
sensitization by AA was only partially inhibited by Y-27632 in
K-toxin-permeabilized and not signi¢cantly in smooth muscle
extensively permeabilized with Triton X-100, we suggest that
AA can act by a dual mechanism: (i) activation of Rho-kinase
(or related kinase) [12,34] directly, and/or by dissociating the
RhoAWguanine nucleotide dissociation inhibitor (GDI) com-
plex [35] and acting as a guanine nucleotide exchange factor
(GEF) for p21RhoA, similar to its e¡ect on RacWGDI, and (ii)
direct inhibition of SMPP-1M [10]. AA may also contribute to
activation of Rho-kinase by agonists that release endogenous
AA [11], but in that case it remains to be explained why AA
released by PDBu [11] does not have this e¡ect, as indicated
by the resistance of PDBu-induced Ca2-sensitization to Y-
27632 (present study) and to ADP-ribosylation of RhoA [22].
Compared to its high potency in reversing GTPQS-induced
Ca2-sensitization, pre-treatment with Y-27632 was, surpris-
ingly, less e¡ective (Fig. 3). We can only speculate that this
may indicate a dual site of action of Y-27632 on P160
ROCK: binding at one site of the inactive enzyme may imply
inhibition at the catalytic site of the activated form. Alterna-
tively, in situ exposure of SMPP-1M to Y-27632 may reduce
its sensitivity to inhibition by Rho-kinase. It is interesting that
Y-27632 dramatically reduced the blood pressure in three
types of experimentally hypertensive rats, without having a
major e¡ect on normotensives [1]. The underlying assumption,
then, would be that Rho-kinase was activated in the hyper-
tensives, but not in normotensive controls. Our ¢ndings sug-
gest that Y-27632 would reduce excitatory (e.g. K-adrenergic)
agonist-induced increases in blood pressure of normotensive
animals, but would be less e¡ective in preventing such re-
sponses.
Phorbol ester-induced Ca2-sensitization was resistant to
concentrations of Y-27632 that nearly completely blocked
the e¡ects of GTPQS (Fig. 2). Thus, although in solution the
selectivity of Y-27632 for P160 ROCK compared to brain
kinase C is somewhat limited [1], in situ the conventional
and novel PKCs that are activated by phorbol esters are not
inhibited by concentrations of Y-27632 that inhibit the
G-protein-coupled mechanisms. The resistance of PDBu-
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Fig. 5. Ca2-sensitizing pathways in smooth muscle. Force devel-
oped by smooth muscle is proportional, albeit not necessarily line-
arly, to the level of MLC20 phosphorylation by Ca2-calmodulin-de-
pendent MLCK. A major physiological Ca2-sensitizing mechanism
is initiated by the binding of an excitatory agonist to its receptor,
activation and translocation of p21rhoA to the cell membrane [22],
and activation of Rho-kinase by Rho. Phosphorylation by Rho-kin-
ase inhibits SMPP-1M, resulting in increased MLC20 phosphoryla-
tion in the continued presence of MLCK activity. This pathway can
also be activated by AA, as indicated by the partial inhibition of
the Ca2-sensitizing e¡ect of AA on force by the Rho-kinase inhibi-
tor, Y-27632. AA can also inhibit SMPP-1M through another mech-
anism that is not inhibited by Y-27632. Phorbol ester-activated con-
ventional and novel kinase Cs (PKCc;n) phosphorylate and so
activate the SMPP-1M inhibitor, CPI-17 [20], and inhibit dephos-
phorylation of MLC20 independently of Rho-kinase. Thus several
di¡erent upstream mechanisms converge to inhibit dephosphoryla-
tion of MLC20, resulting in Ca2-sensitization. SMPP-1M, smooth
muscle myosin phosphatase; MLCK, myosin light chain kinase;
MLC20, regulatory smooth muscle myosin light chain; MLC20p,
MLC20 phosphorylated on the serine 19; PKC, protein kinase C;
CPI-17p, CPI-17 phosphorylated by PKC [20].
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induced e¡ects to Y-27632 is consistent with the conclusion
that phorbol esters and the conventional and novel PKCs
activated by them operate predominantly through di¡erent
upstream mechanisms than the physiological, G-protein-
coupled ones [8,36,37]. A recent preliminary report [38] of
airway smooth muscle also implicates P160 ROCK, rather
than conventional and novel PKCs, in G-protein-coupled
Ca2-sensitization. The several Ca2-sensitizing pathways
converging on inhibition of SMPP-1M are shown in the
scheme of Fig. 5 (see also [2,39]).
The relaxation of submaximal Ca2-induced contractions of
K-toxin-permeabilized smooth muscles by Y-27632 is of tech-
nical interest. Our results are consistent with previous studies
that have suggested that inhibition of the RhoA pathway
could reduce force developed in response to submaximal ele-
vations of Ca2 in smooth muscles permeabilized with L-escin
[10], and in one study GDPLS induced a shift in the pCa
tension curve [31]. These e¡ects of Y-27632 are not due to
partial inhibition of MLCK (Kis 250 WM) [1], because (sub-
maximal) Ca2-induced tension is not a¡ected in smooth
muscles in which the G-protein-coupled pathway was elimi-
nated through extensive permeabilization with Triton X-100
(present study).
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